Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8797 |
High Similarity |
NPD3027 |
Phase 3 |
0.8582 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8507 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8467 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8467 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8444 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8321 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.8248 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.8235 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.8129 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.8074 |
Intermediate Similarity |
NPD4749 |
Approved |
0.8074 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.8074 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.8062 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.806 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.8 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7987 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7975 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7971 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7908 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7895 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7843 |
Intermediate Similarity |
NPD37 |
Approved |
0.7801 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.777 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7769 |
Intermediate Similarity |
NPD228 |
Approved |
0.7727 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7707 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7692 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7692 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7692 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7619 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7615 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7582 |
Intermediate Similarity |
NPD1653 |
Approved |
0.758 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7578 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7578 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7578 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7569 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7569 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7566 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7564 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7554 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7554 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7551 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7537 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7533 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7517 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7517 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7481 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7481 |
Intermediate Similarity |
NPD3021 |
Approved |
0.747 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7434 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7434 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7432 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7432 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7419 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.741 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7407 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7403 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7386 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7378 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7376 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7368 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7358 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7347 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7347 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7344 |
Intermediate Similarity |
NPD940 |
Approved |
0.7344 |
Intermediate Similarity |
NPD846 |
Approved |
0.7338 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7329 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7329 |
Intermediate Similarity |
NPD5494 |
Approved |
0.732 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.732 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.732 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7315 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7313 |
Intermediate Similarity |
NPD7635 |
Approved |
0.7312 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7312 |
Intermediate Similarity |
NPD4055 |
Discovery |
0.731 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7299 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7296 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7286 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7285 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7284 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7273 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7266 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7266 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7261 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7261 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7248 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7237 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7233 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD6746 |
Phase 2 |
0.7218 |
Intermediate Similarity |
NPD5451 |
Approved |
0.7211 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7211 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7197 |
Intermediate Similarity |
NPD7261 |
Clinical (unspecified phase) |
0.7197 |
Intermediate Similarity |
NPD2342 |
Discontinued |
0.719 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.7186 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7181 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.7176 |
Intermediate Similarity |
NPD8053 |
Approved |
0.7176 |
Intermediate Similarity |
NPD8054 |
Approved |
0.7171 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7169 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7163 |
Intermediate Similarity |
NPD1611 |
Approved |
0.7152 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7152 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD6788 |
Approved |
0.7143 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7133 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7126 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7124 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7123 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7121 |
Intermediate Similarity |
NPD968 |
Approved |
0.7115 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.711 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7101 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7095 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7083 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7081 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7075 |
Intermediate Similarity |
NPD5111 |
Phase 2 |
0.7075 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7075 |
Intermediate Similarity |
NPD5109 |
Approved |
0.7075 |
Intermediate Similarity |
NPD5110 |
Phase 2 |
0.7071 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7071 |
Intermediate Similarity |
NPD1651 |
Approved |
0.7063 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.7063 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7059 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7054 |
Intermediate Similarity |
NPD3020 |
Approved |
0.7051 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD3657 |
Discovery |
0.7042 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7041 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7039 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7039 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7039 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7034 |
Intermediate Similarity |
NPD4624 |
Approved |
0.703 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7029 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7021 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7021 |
Intermediate Similarity |
NPD5846 |
Approved |
0.702 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.702 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7019 |
Intermediate Similarity |
NPD6818 |
Clinical (unspecified phase) |
0.7019 |
Intermediate Similarity |
NPD5929 |
Approved |
0.7015 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7014 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7014 |
Intermediate Similarity |
NPD2922 |
Phase 1 |
0.7013 |
Intermediate Similarity |
NPD7466 |
Approved |
0.7013 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7007 |
Intermediate Similarity |
NPD1398 |
Phase 1 |
0.7 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7 |
Intermediate Similarity |
NPD289 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD5090 |
Approved |
0.7 |
Intermediate Similarity |
NPD5089 |
Approved |
0.6993 |
Remote Similarity |
NPD1549 |
Phase 2 |
0.6993 |
Remote Similarity |
NPD2233 |
Approved |
0.6993 |
Remote Similarity |
NPD2232 |
Approved |
0.6993 |
Remote Similarity |
NPD2230 |
Approved |
0.6993 |
Remote Similarity |
NPD970 |
Clinical (unspecified phase) |
0.6988 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.6987 |
Remote Similarity |
NPD7390 |
Discontinued |
0.6987 |
Remote Similarity |
NPD7041 |
Phase 2 |
0.6987 |
Remote Similarity |
NPD7040 |
Clinical (unspecified phase) |
0.6981 |
Remote Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.698 |
Remote Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.6978 |
Remote Similarity |
NPD7340 |
Approved |
0.6975 |
Remote Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.6972 |
Remote Similarity |
NPD3496 |
Discontinued |
0.6968 |
Remote Similarity |
NPD6190 |
Approved |
0.6968 |
Remote Similarity |
NPD5241 |
Discontinued |
0.6966 |
Remote Similarity |
NPD3094 |
Phase 2 |
0.6964 |
Remote Similarity |
NPD8099 |
Discontinued |
0.6964 |
Remote Similarity |
NPD8251 |
Approved |
0.6964 |
Remote Similarity |
NPD8252 |
Approved |
0.6959 |
Remote Similarity |
NPD7808 |
Phase 3 |
0.6954 |
Remote Similarity |
NPD4536 |
Approved |
0.6954 |
Remote Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD4538 |
Approved |
0.6953 |
Remote Similarity |
NPD2860 |
Approved |
0.6953 |
Remote Similarity |
NPD844 |
Approved |
0.6953 |
Remote Similarity |
NPD2859 |
Approved |
0.695 |
Remote Similarity |
NPD5691 |
Approved |
0.6948 |
Remote Similarity |
NPD4236 |
Phase 3 |
0.6948 |
Remote Similarity |
NPD4237 |
Approved |
0.6948 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6943 |
Remote Similarity |
NPD4123 |
Phase 3 |
0.6943 |
Remote Similarity |
NPD2532 |
Approved |
0.6943 |
Remote Similarity |
NPD2533 |
Approved |
0.6943 |
Remote Similarity |
NPD2534 |
Approved |
0.6941 |
Remote Similarity |
NPD6797 |
Phase 2 |
0.6937 |
Remote Similarity |
NPD6599 |
Discontinued |
0.6936 |
Remote Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.6934
|
Remote Similarity |
NPD7843 |
Approved |